| (Values in U.S. Thousands) | Dec, 2024 | Sep, 2024 | Jun, 2024 | Mar, 2024 | Dec, 2023 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -2,400 | -2,040 | -1,690 | -1,720 | -5,790 |
| Net Income Growth | -17.65% | -20.71% | +1.74% | +70.29% | -61.28% |
Mira Pharmaceuticals Inc (MIRA)
0.9900 +0.0100 (+1.02%) 13:29 ET [NASDAQ]
0.9700 x 2 1.0000 x 3
Realtime by (Cboe BZX)
0.9700 x 2 1.0000 x 3
Realtime 0.9900 +0.0100 (-) 09:28 ET
for Tue, Apr 1st, 2025
MIRA Pharmaceuticals Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. MIRA Pharmaceuticals Inc. is based in Baltimore, Maryland.
Fiscal Year End Date: 12/31